Top of page Skip navigation
  • ARE YOU JOINING US ON 8 JUNE?

    Over 60% of places already booked - register your place today...

  • ARE YOU JOINING US ON 8 JUNE?

    Over 60% of places already booked - register your place today...

Presentations from the 2016 conference

Innovation and accelerated access in the UK – Where are we today?

European perspective: Results of survey on early access schemes / compassionate use of new medicines

Kate Beaujeux, Regulatory Affairs Senior Regional Director, Oncology, AstraZeneca

Review of the UK Early Access to Medicines Scheme

The Early Access to Medicines Scheme (EAMS): Two years on

Dr Daniel O’Connor, Expert Medical Assessor, Licensing Division, Medicines and Healthcare products Regulatory Agency

Industry experience: Case study – Keytruda granted the first positive EAMS scientific opinion

Joanna Maitland Smith, Executive Director Regulatory Affairs, MSD

NICE perspective

Dr Nick Crabb, Programme Director, Scientific Affairs, National Institute for Health and Care Excellence 

NHS England perspective

Malcolm Qualie, Pharmacy Lead, Specialised Services, NHS England

Supporting innovation and optimising development pathways

EU early access tools: Overview

Robert Hemmings, Manager, Licensing Division, Medicines and Healthcare products Regulatory Agency, and Chair, CHMP’s Scientific Advice Working Party, European Medicines Agency

EMA's adaptive pathways pilot project

Francesca Cerreta, Senior Scientific Officer, European Medicines Agency

NICE perspective

Professor Sarah Garner, Associate Director, Science Policy and Research, National Institute for Health and Care Excellence 

The new EMA’s PRIME (Priority Medicines) scheme

Dr Jordi Llinares, Head of Product Development Scientific Support Department, European Medicines Agency

Industry experience with FDA’s breakthrough therapy designation: Case study – Approval of Blincyto

Rhian Thomas, Executive Director, Global Regulatory Affairs, Amgen